PMID- 32195932
OWN - NLM
STAT- MEDLINE
DCOM- 20200406
LR  - 20221005
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 12
DP  - 2020 Mar
TI  - Drug-eluting beads transarterial chemoembolization by CalliSpheres is effective 
      and well tolerated in treating intrahepatic cholangiocarcinoma patients: A 
      preliminary result from CTILC study.
PG  - e19276
LID - 10.1097/MD.0000000000019276 [doi]
LID - e19276
AB  - This study aimed to investigate the efficacy and safety of drug-eluting beads 
      (DEB) transarterial chemoembolization (TACE) treatment in Chinese intrahepatic 
      cholangiocarcinoma (ICC) patients.37 ICC patients underwent DEB-TACE treatment in 
      CTILC study (registered on clinicaltrials.gov with registry No. NCT03317483) were 
      included in this present study. Treatment response was assessed according to 
      modified Response Evaluation Criteria in Solid Tumors (mRECIST). Overall survival 
      (OS) was calculated from the time of DEB-TACE operation until the date of death 
      from any causes. Liver function change and adverse events (AEs) were recorded 
      during and after DEB-TACE operation.3 (8.1%) patients achieved complete response 
      (CR) and 22 (59.5%) patients achieved partial response (PR), with objective 
      response rate (ORR) of 67.6%. After DEB-TACE treatment, mean OS was 376 days 
      (95%CI: 341-412 days). Multivariate logistic regression analysis revealed that 
      Bilobar disease (P = .040, OR: 0.105, 95% CI: 0.012-0.898) and portal vein 
      invasion (P = .038, OR: 0.104, 95% CI: 0.012-0.881) could independently predict 
      less possibility of ORR. Patients with ALB abnormal, TP abnormal, ALT abnormal 
      and AST abnormal were increased at 1-week post DEB-TACE treatment (P = .034, 
      P = .001, P < .001, P = .006, respectively), while returned to the levels at 
      baseline after 1 to 3 months (all P > .050). Besides, most of the AEs were mild 
      including pain, fever, vomiting, and nausea in this study.DEB-TACE was effective 
      and well tolerated in treating ICC patients, and bilobar disease as well as 
      portal vein invasion were independently correlated with less probability of ORR 
      achievement.
FAU - Luo, Jun
AU  - Luo J
AD  - Department of Intervention, Zhejiang Cancer Hospital, Hangzhou.
FAU - Zheng, Jiaping
AU  - Zheng J
AD  - Department of Intervention, Zhejiang Cancer Hospital, Hangzhou.
FAU - Shi, Changsheng
AU  - Shi C
AD  - Department of Intervention, The Third Affiliated Hospital of Wenzhou Medical 
      University, Ruian, China.
FAU - Fang, Jian
AU  - Fang J
AD  - Department of Hepatobiliary Surgery, Quzhou People's Hospital, Quzhou.
FAU - Peng, Zhiyi
AU  - Peng Z
AD  - Department of Radiology, The First Affiliated Hospital, College of Medicine, 
      Zhejiang University, Hangzhou.
FAU - Huang, Jing
AU  - Huang J
AD  - Department of Hepatobiliary Surgery, Ningbo Medical Center, Lihuili Eastern 
      Hospital, Ningbo.
FAU - Sun, Junhui
AU  - Sun J
AD  - Hepatobiliary and Pancreatic Interventional Treatment Center, Division of 
      Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, College of 
      Medicine, Zhejiang University, Hangzhou.
FAU - Zhou, Guanhui
AU  - Zhou G
AD  - Hepatobiliary and Pancreatic Interventional Treatment Center, Division of 
      Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, College of 
      Medicine, Zhejiang University, Hangzhou.
FAU - Li, Tiefeng
AU  - Li T
AD  - Department of Radiology, Beilun District People's Hospital of Ningbo, Ningbo.
FAU - Zhu, Dedong
AU  - Zhu D
AD  - Department of Liver Oncology, Ningbo No.2 Hospital, Ningbo, China.
FAU - Xu, Huanhai
AU  - Xu H
AD  - Division of Digestive Endoscopy, Yueqing City People's Hospital, Yueqing.
FAU - Hou, Qinming
AU  - Hou Q
AD  - Department of Radiology, Xixi Hospital of Hangzhou, Hangzhou 6th People's 
      Hospital, Hangzhou.
FAU - Ying, Shihong
AU  - Ying S
AD  - Department of Radiology, The First Affiliated Hospital, College of Medicine, 
      Zhejiang University, Hangzhou.
FAU - Sun, Zhichao
AU  - Sun Z
AD  - Department of Radiology, The First Affiliated Hospital of Zhejiang Chinese 
      Medical University, Hangzhou.
FAU - Du, Haijun
AU  - Du H
AD  - Department of Intervention, Dong Yang people's Hospital, Dongyang.
FAU - Xie, Xiaoxi
AU  - Xie X
AD  - Interventional Center, Xinchang People's Hospital, Shaoxing.
FAU - Cao, Guohong
AU  - Cao G
AD  - Department of Radiology, Shulan (Hangzhou) Hospital, Zhejiang University 
      International Hospital, Hangzhou.
FAU - Ji, Wenbin
AU  - Ji W
AD  - Department of Radiology, Taizhou Hospital of Zhejiang Province, Linhai.
FAU - Han, Jun
AU  - Han J
AD  - Department of Intervention, Jiaxing First Hospital, Jiaxing.
FAU - Gu, Wenjiang
AU  - Gu W
AD  - Department of Intervention, Jiaxing Second Hospital, Jiaxing.
FAU - Guo, Xiaohua
AU  - Guo X
AD  - Department of Intervention, Jinhua Central Hospital, Jinhua.
FAU - Shao, Guoliang
AU  - Shao G
AD  - Department of Intervention, Zhejiang Cancer Hospital, Hangzhou.
FAU - Yu, Zhihai
AU  - Yu Z
AD  - Department of Vascular and Interventional Radiology, The Affiliated Hospital of 
      Medical College of Ningbo University, Ningbo.
FAU - Zhou, Jian
AU  - Zhou J
AD  - Department of Radiology, Hangzhou Cancer Hospital.
FAU - Yu, Wenqiang
AU  - Yu W
AD  - Department of Intervention, Zhejiang Provincial People's Hospital, Hangzhou, 
      China.
FAU - Zhang, Xin
AU  - Zhang X
AD  - Department of Radiology, The First Affiliated Hospital, College of Medicine, 
      Zhejiang University, Hangzhou.
FAU - Li, Ling
AU  - Li L
AD  - Department of Liver Oncology, Ningbo No.2 Hospital, Ningbo, China.
FAU - Hu, Hongjie
AU  - Hu H
AD  - Department of Radiology, Sir Run Run Shaw Hospital, Zhejiang University College 
      of Medicine, Hangzhou.
FAU - Hu, Tingyang
AU  - Hu T
AD  - Department of Intervention, Zhejiang Provincial People's Hospital, Hangzhou, 
      China.
FAU - Wu, Xia
AU  - Wu X
AD  - Department of Radiology, Sir Run Run Shaw Hospital, Zhejiang University College 
      of Medicine, Hangzhou.
FAU - Chen, Yutang
AU  - Chen Y
AD  - Department of Intervention, Zhejiang Cancer Hospital, Hangzhou.
FAU - Ji, Jiansong
AU  - Ji J
AD  - Department of Radiology, Lishui Central Hospital, Lishui Hospital of Zhejiang 
      University, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui.
FAU - Hu, Wenhao
AU  - Hu W
AD  - Department of Intervention, The First Affiliated Hospital of Wenzhou Medical 
      University, Wenzhou, China.
LA  - eng
SI  - ClinicalTrials.gov/NCT03317483
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 80168379AG (Doxorubicin)
SB  - IM
MH  - Aged
MH  - Bile Duct Neoplasms/pathology/*therapy
MH  - Chemoembolization, Therapeutic/*methods
MH  - Cholangiocarcinoma/pathology/*therapy
MH  - Doxorubicin
MH  - Drug Delivery Systems
MH  - Female
MH  - Humans
MH  - Liver Neoplasms/secondary
MH  - Logistic Models
MH  - Male
MH  - Microspheres
MH  - Middle Aged
MH  - Neoplasm Invasiveness
MH  - Portal Vein/pathology
PMC - PMC7220404
COIS- The authors have no conflicts of interests to disclose.
EDAT- 2020/03/21 06:00
MHDA- 2020/04/09 06:00
PMCR- 2020/03/20
CRDT- 2020/03/21 06:00
PHST- 2020/03/21 06:00 [entrez]
PHST- 2020/03/21 06:00 [pubmed]
PHST- 2020/04/09 06:00 [medline]
PHST- 2020/03/20 00:00 [pmc-release]
AID - 00005792-202003200-00010 [pii]
AID - MD-D-19-05003 [pii]
AID - 10.1097/MD.0000000000019276 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Mar;99(12):e19276. doi: 10.1097/MD.0000000000019276.